Wanebo Harold J, Argiris Athanassios, Bergsland Emily, Agarwala Sanjiv, Rugo Hope
Department of Surgery, Division Surgical Oncology, Roger Williams Medical Center, Providence, RI, USA.
Cancer Metastasis Rev. 2006 Jun;25(2):279-92. doi: 10.1007/s10555-006-8508-2.
Targeted biologic therapy for cancer has evolved from the laboratory to active clinical protocols and applied clinical practice in selected patients. Major targets include epidermal growth factor, and vascular endothelial growth factor receptors which are commonly expressed in gastro-intestinal cancers head & neck and lung cancers, and to some degree breast and gynecologic malignancy. Down stream signal transduction pathway inhibition of B-raf and N-ras mutations are examined in melanoma. New approaches involving re-packaging of chemotherapeutic agents are being exemplified in the nanoparticle formulation of paclitaxel which provides increased access to endothelial and tumor cells with potential enhanced therapeutic efficacy compared to the conventional version solubilized in a cremophor.
癌症的靶向生物治疗已从实验室发展到积极的临床方案，并应用于特定患者的临床实践。主要靶点包括表皮生长因子和血管内皮生长因子受体，它们在胃肠道癌、头颈癌和肺癌中普遍表达，在一定程度上也见于乳腺癌和妇科恶性肿瘤。在黑色素瘤中研究了对B-raf和N-ras突变的下游信号转导通路抑制。涉及重新包装化疗药物的新方法在紫杉醇纳米颗粒制剂中得到体现，与溶解在聚氧乙烯蓖麻油中的传统制剂相比，该制剂能增加对内皮细胞和肿瘤细胞的作用，可能具有更高的治疗效果。
